NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02659293,"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma",https://clinicaltrials.gov/study/NCT02659293,,ACTIVE_NOT_RECRUITING,"This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.",NO,Multiple Myeloma,DRUG: Lenalidomide|DRUG: Carfilzomib|DRUG: Dexamethasone|DRUG: Lenalidomide (Control),"Progression free survival rates in participants receiving drug combination, Measurement of time to disease worsening as measured by International Myeloma Working Group (IMWG) response criteria., 4 years","Rate of minimal residual negative disease (MRD) in participants receiving drug combination, Calculation of number of participants with MRD-negative disease., 3 years|Response rate in participants receiving drug combination, Number of participants with disease response (e.g. improvement) as measured by International Myeloma Working Group (IMWG) response criteria., 3 years|Treatment-related side effects, Number of participants with grade 2 or greater treatment-related side effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0, From date of screening until end of treatment",,University of Chicago,,ALL,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IRB15-1286,2016-04-26,2025-11,2026-11,2016-01-20,,2025-03-25,"University of Chicago, Chicago, Illinois, 60637, United States|Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, 48201, United States|Polish Myeloma Consortium, Pozna≈Ñ, Poland",
